Testimony on Fluticasone/Vilanterol Combination Therapy to the FDA’s Pulmonary-Allergy Drugs Advisory Committee

View as PDF.

View press release

The Food and Drug Administration (FDA) should not approve the proposed combination therapy, fluticasone/vilanterol (proposed trade name: Breo Ellipta) for the treatment of chronic obstructive pulmonary disease (COPD), because the drug is largely ineffective and causes serious side effects compared with vilanterol given alone, and was studied in a series of unethical clinical trials.

April 30, 2013 Letter to FDA Opposing Approval of Fluticasone Furoate/Vilanterol (FF/VI) for COPD